首页> 外文OA文献 >In SilicoScreening of the Library of Pyrimidine Derivatives as Thymidylate Synthase Inhibitors for Anticancer Activity
【2h】

In SilicoScreening of the Library of Pyrimidine Derivatives as Thymidylate Synthase Inhibitors for Anticancer Activity

机译:在嘧啶衍生物库中的硅筛选,作为抗癌活性的胸苷合酶抑制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We here report the virtual screening of several series of pyrimidine derivatives for in silico Thymidylate Synthase (TS) inhibition to arrive at possible potential inhibitors of TS with acceptable pharmacokinetic or ADME (Absorption, Distribution, Metabolism and Excretion) properties. Library of the molecules was constructed based upon structural modifications of pyrimidines nucleus. Structural modifications in descending order were performed for the series of pyrimidines, viz from pyrimidines with five membered heterocyclic ring to pyrimidines with four membered heterocyclic ring to simple pyrimindine carboxylates in an order to arrive at pyrimidines with better inhibition scores (G-Scores) as compared with Raltitrexed (RTX) and active metabolite of 5-Fluorouracil (5-FUMP). The molecules with better G-Scores were subjected to predict pharmacokinetic or ADME properties. The molecules with acceptable ADME properties and better G-Scores were prioritized for synthesis and anticancer evaluation. Three molecules from pyrimidine carboxylate series PIC1-31 were found acceptable with G-Scores and pharmacokinetic properties. Thus a library of pyrimidine derivatives was constructed based upon the feasibility of synthesis and in silico screened to prioritize the molecules and to obtain potential lead molecules as TS inhibitors.
机译:我们在这里报道了在硅胸苷合酶(TS)抑制中的几种嘧啶衍生物的虚拟筛选,以获得TS的可能潜在抑制剂,具有可接受的药代动力学或ADME(吸收,分布,代谢和排泄)性质。基于嘧啶核的结构修饰构建分子库。降序排列结构修饰被用于在一系列嘧啶的执行,从具有五个嘧啶即相比于为了在嘧啶具有更好的抑制评分(G-分数),以到达元杂环到嘧啶四元杂环的环,以简单pyrimindine羧酸盐用roltitrexed(RTX)和5-氟尿嘧啶(5级)的活性代谢物。进行具有更好G谱的分子预测药代动力学或ADME特性。优先考虑具有可接受的Adme特性和更好的G分子的分子进行合成和抗癌评估。发现来自嘧啶羧酸酯系列PIC1-31的三种分子可接受G谱和药代动力学性质。因此,基于合成的可行性和硅藻土的可行性构建了嘧啶衍生物,以优先考虑潜在的铅分子作为TS抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号